MET and neoplasm: The recently developed IgG2-enhanced next generation MET monoclonal antibody KTN0073 exhibits potent anti-tumor properties both in vitro and in vivo, not only on MET-amplified cells, but also in the juxta-membrane exon 14 deletion mutants [52].